miR-424(322) reverses chemoresistance via T-cell immune response activation by blocking the PD-L1 immune checkpoint

Shaohua Xu,Zhen Tao,Bo Hai,Huagen Liang,Ying Shi,Tao Wang,Wen Song,Yong Chen,Jun OuYang,Jinhong Chen,Fanfei Kong,Yishan Dong,Shi-Wen Jiang,Weiyong Li,Ping Wang,Zhiyong Yuan,Xiaoping Wan,Chenguang Wang,Wencheng Li,Xiaoping Zhang,Ke Chen

DOI: https://doi.org/10.1038/ncomms11406

IF: 16.6

2016-05-05

Nature Communications

Abstract:Immune checkpoint blockade of the inhibitory immune receptors PD-L1, PD-1 and CTLA-4 has emerged as a successful treatment strategy for several advanced cancers. Here we demonstrate that miR-424(322) regulates the PD-L1/PD-1 and CD80/CTLA-4 pathways in chemoresistant ovarian cancer. miR-424(322) is inversely correlated with PD-L1, PD-1, CD80 and CTLA-4 expression. High levels of miR-424(322) in the tumours are positively correlated with the progression-free survival of ovarian cancer patients. Mechanistic investigations demonstrated that miR-424(322) inhibited PD-L1 and CD80 expression through direct binding to the 3′-untranslated region. Restoration of miR-424(322) expression reverses chemoresistance, which is accompanied by blockage of the PD-L1 immune checkpoint. The synergistic effect of chemotherapy and immunotherapy is associated with the proliferation of functional cytotoxic CD8+ T cells and the inhibition of myeloid-derived suppressive cells and regulatory T cells. Collectively, our data suggest a biological and functional interaction between PD-L1 and chemoresistance through the microRNA regulatory cascade.

multidisciplinary sciences